Therapeutic effect of irbesartan combined metoprolol on patients with chronic heart failure complicated atrial or ventricular arrhythmia／
10.3969/j.issn.1008－0074.2019.04.19
- VernacularTitle:厄贝沙坦联合美托洛尔治疗慢性心力衰竭合并房性或室性心律失常患者的疗效
- Author:
Yun LI
1
;
Ri‐yang GAO
;
Xiao‐liang LIN
;
Jing YANG
Author Information
1. 海口市第四人民医院心血管内科
- Keywords:
Heart failure;
Arrhythmias,cardiac;
Metoprolol;
Erbesartan
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2019;28(4):466-469
- CountryChina
- Language:Chinese
-
Abstract:
To explore therapeutic effect of irbesartan combined metoprolol on patients with chronic heart failure (CHF) complicated atrial or ventricular arrhythmia .Methods : A total of 168 CHF patients with atrial or ventricular arrhythmia treated in our hospital from 2017 were randomly and equally divided into metoprolol group (re‐ceived metoprolol based on routine treatment ) and combined treatment group (received irbesartan based on metoprolol group) , both groups were treated for three months .LVEF , left ventricular posterior wall thickness (LVPWT) , interven‐tricular septal thickness (IVST) before and after treatment , therapeutic effect were observed and compared between two groups.Results : Total effective rate of combined treatment group was significantly higher than that of metoprolol group (90.5% vs.73.8%) , P＝ 0.005. Compared with before treatment , there was significant rise in LVEF [ (55.16 ± 6.52)% vs.(64.24 ± 8.72)%] , and significant reductions in LVPWT [ (14.72 ± 1.78) mm vs.(13.27 ± 1.14) mm] , IVST [ (10.18 ± 1.15) mm vs.(9.12 ± 0.64) mm] in combined treatment group after treatment , P＝0.001 all ;and compared with metoprolol group after three‐month treatment , there was significant rise in LVEF [ (56.13 ± 6.15)%vs.(64. 24 ± 8.72)%] , and significant reductions in LVPWT [ (14. 35 ± 1. 23) mm vs.(13.27 ± 1.14) mm] and IVST [(9. 88 ± 0.85) mm vs.(9. 12 ± 0. 64) mm] in combined treatment group , P＝0. 001 all.There was no signif‐icant difference in incidence rate of adverse between two groups , P＝ 0.799. Conclusion : Irbesartan combined metoprolol possess significant therapeutic effect on patients with CHF complicated atrial or ventricular arrhythmia with good safety .Inhibition on ventricular remodeling may be its main mechanism .
